Transdermal lidocaine as treatment for chronic subjective tinnitus

: A pilot study Publication date: Available online 18 March 2019 Source: American Journal of Otolaryngology Author(s): Daniel C. O'Brien, Aaron D. Robinson, Nancy Wang, Rodney Diaz Abstract Objective To assess the efficacy of transdermal lidocaine as a treatment for chronic subjective tinnitus as measured by the Tinnitus Functional Index (TFI). Study design Pilot, prospective efficacy trial. Setting Tertiary care hospital. Patients Men and women, over the age of 18 with chronic subjective tinnitus for >6 months. Intervention Daily application of commercially available transdermal lidocaine patch. Outcome measure Change in the TFI. Results The average pre-treatment TFI score was 56.2. After 1 month the average TFI decreased to 41 (p < 0.05). The scores dropped to 34 and 35 after 2 and 3 months of treatment respectively. Despite improvement in symptoms of tinnitus, most patients did not continue the study after the first month, dropping out due to the size, discomfort, and appearance of the lidocaine patch, failure to follow-up and lack of perceived benefit from treatment. Conclusions In this preliminary study, 5% transdermal lidocaine appears to be a potential treatment for chronic subjective tinnitus. The majority of subjects who completed 1 month of treatment had clinically significantly improved tinnitus. These findings are confounded however by the small sample size and significant drop out rate.